Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Thomas Müller. (2023) The role of istradefylline in the Parkinson’s disease armamentarium. Expert Opinion on Pharmacotherapy 24:7, pages 863-871.
Read now
Read now
Kanako Kurihara, Takayasu Mishima, Shinsuke Fujioka & Yoshio Tsuboi. (2022) Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for parkinson’s disease. Expert Opinion on Drug Safety 21:2, pages 137-147.
Read now
Read now
Thomas Müller. (2020) Pharmacokinetics and pharmacodynamics of levodopa/carbidopa cotherapies for Parkinson’s disease. Expert Opinion on Drug Metabolism & Toxicology 16:5, pages 403-414.
Read now
Read now
Thomas Müller. (2018) ABCB1: is there a role in the drug treatment of Parkinson’s disease?. Expert Opinion on Drug Metabolism & Toxicology 14:2, pages 127-129.
Read now
Read now
Articles from other publishers (18)
Ying Wang, Guan-An Zhao, Xia Li, En Zhang, Wei Tan & Jia-qi Chen. (2023) Establishment of a sensitive UPLC-MS/MS method to quantify safinamide in rat plasma. Frontiers in Pharmacology 14.
Crossref
Crossref
Heba M. El-Sayed, Hisham Ezzat Abdellatef, Amr M. Mahmoud, Hassan A.M. Hendawy, Omar M El-Abassy & Hany Ibrahim. (2023) Safinamide detection based on Prussian blue analogue modified Solid-contact potentiometric sensor. Microchemical Journal 191, pages 108829.
Crossref
Crossref
Heba M. El-Sayed, Hisham Ezzat Abdellatef, Hassan A.M. Hendawy, Omar M El-Abassy & Hany Ibrahim. (2023) DoE-enhanced development and validation of eco-friendly RP-HPLC method for analysis of safinamide and its precursor impurity: QbD approach. Microchemical Journal 190, pages 108730.
Crossref
Crossref
Heba M El-Sayed, Omar M El-Abassy, Hisham Ezzat Abdellatef, Hassan A M Hendawy & Hany Ibrahim. (2023) Green Spectrophotometric Platforms for Resolving Overlapped Spectral Signals of Recently Approved Antiparkinsonian Drug (Safinamide) in the Presence of Its Synthetic Precursor (4-Hydroxybenzaldehyde): Applying Ecological Appraisal and Comparative Statistical Studies. Journal of AOAC INTERNATIONAL 106:1, pages 26-33.
Crossref
Crossref
Heba M El-sayed, Ahmed M. Abdel-Raoof, Hisham Ezzat Abdellatef, Hassan A.M. Hendawy, Omar M El-Abassy & Hany Ibrahim. (2022) Versatile eco-friendly electrochemical sensor based on chromium-doped zinc oxide nanoparticles for determination of safinamide aided by green assessment criteria. Microchemical Journal 182, pages 107900.
Crossref
Crossref
Yu-Yan Tan, Peter Jenner & Sheng-Di Chen. (2022) Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson’s Disease: Past, Present, and Future. Journal of Parkinson's Disease 12:2, pages 477-493.
Crossref
Crossref
Sonali S. Bharate. (2021) Modulation of biopharmaceutical properties of drugs using sulfonate counterions: A critical analysis of FDA-approved pharmaceutical salts. Journal of Drug Delivery Science and Technology 66, pages 102913.
Crossref
Crossref
Rona R. Ramsay & Alen Albreht. (2021) Questions in the Chemical Enzymology of MAO. Chemistry 3:3, pages 959-978.
Crossref
Crossref
Himika Wasan, Devendra Singh & Reeta KH. (2021) Safinamide in neurological disorders and beyond: Evidence from preclinical and clinical studies. Brain Research Bulletin 168, pages 165-177.
Crossref
Crossref
Sonali S. Bharate. (2021) Recent developments in pharmaceutical salts: FDA approvals from 2015 to 2019. Drug Discovery Today 26:2, pages 384-398.
Crossref
Crossref
Juan Segura-Aguilar. 2021. Clinical Studies and Therapies in Parkinson's Disease. Clinical Studies and Therapies in Parkinson's Disease
173
185
.
Alberto Corsini, Nicola Ferri, Marco Proietti & Giuseppe Boriani. (2020) Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice. Drugs 80:11, pages 1065-1083.
Crossref
Crossref
Javier Pagonabarraga, José Matías Arbelo, Francisco Grandas, Maria-Rosario Luquin, Pablo Martínez Martín, Mari Cruz Rodríguez-Oroz, Francesc Valldeoriola & Jaime Kulisevsky. (2020) A Spanish Consensus on the Use of Safinamide for Parkinson’s Disease in Clinical Practice. Brain Sciences 10:3, pages 176.
Crossref
Crossref
Michinori KoebisuTakayuki Ishida. (2020) Safinamide Mesilate (Equfina<sup>®</sup> TABLETS 50 mg): preclinical and clinical pharmacodynamics, efficacy, and safety新規抗パーキンソン病薬サフィナミドメシル酸塩（エクフィナ<sup>®</sup>錠50 mg）の薬理作用と臨床成績. Folia Pharmacologica Japonica 155:4, pages 269-276.
Crossref
Crossref
Pedro Merino. 2019. Chemical Biology of Neurodegeneration. Chemical Biology of Neurodegeneration
325
357
.
Moussa B. H. Youdim. (2018) Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases. Journal of Neural Transmission 125:11, pages 1719-1733.
Crossref
Crossref
Xu Jiang, Palanivel Ganesan, Thamaraiselvan Rengarajan, Dong-Kug Choi & Palanisamy Arulselvan. (2018) Cellular phenotypes as inflammatory mediators in Parkinson’s disease: Interventional targets and role of natural products. Biomedicine & Pharmacotherapy 106, pages 1052-1062.
Crossref
Crossref
Fábio G. Teixeira, Miguel F. Gago, Paulo Marques, Pedro Silva Moreira, Ricardo Magalhães, Nuno Sousa & António J. Salgado. (2018) Safinamide: a new hope for Parkinson’s disease?. Drug Discovery Today 23:3, pages 736-744.
Crossref
Crossref